期刊文献+

肿瘤内科治疗的发展和现状与对未来的展望 被引量:16

Medical Treatment of Tumors: Development, Status Quo and Prospects
暂未订购
导出
摘要 目的:介绍近40余年来国际和我国在肿瘤内科治疗领域内的发展历程和现状,对本学科的发展前景做了讨论。方法:结合国内外文献进行评价。结果及结论:内科肿瘤学是一门正在发展中的学科。肿瘤研究的各个领域所取得的进展如分子生物学研究、单克隆抗体、化学预防、抗肿瘤药的调节、基因治疗及新药的研究都必然会涉及和促进临床内科治疗的进展。而临床经验的积累、治疗策略和用药艺术的提高,必将进一步提高疗效,给患者带来较大的裨益。 OBEJCTIVE: To introduce the development and the status quo in the medical treatment of tumor both home and abroad and to discuss its prospect. METHODS: We reviewed literatures both home and abroad. RESULTS & CONCLUSION : Medical ontology is a subject undergoing development. The progress made in various areas such as molecular biology, monoclonal antibody, chemoprevention, antineoplastic agents, gene therapy and the research of new drugs would certainly involve and facilitate the progress of clinical medical treatment. With the accumulation of clinical experiences, the improvement in treatment strategies and medication arts, clinical efficacies will necessarily be enhanced for the great benefits of patients.
作者 孙燕
出处 《中国医院用药评价与分析》 2007年第1期6-11,共6页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 肿瘤内科治疗 内科肿瘤学 靶向治疗 治疗个体化 medical treatment of tumor medical ontology targeted therapy individualized therapy
  • 相关文献

参考文献18

  • 1Report of a Join WHO/FAO EXPERT Consultation.Diet,nutrition and the prevention of chronic diseases[M].WHO,Geneva 2003:96~104.
  • 2孙燕.从肿瘤的本质谈预防策略-院士笔下的现代医药[M].福州:福建科学技术出版社,2002:145~152.
  • 3孙燕,谷铣之.肿瘤综合治疗的原则和实践[J].中国肿瘤,1999,8(1):21-23. 被引量:16
  • 4孙燕.中西医结合防治肿瘤的体会和展望[J].中国肿瘤,2003,12(8):436-438. 被引量:34
  • 5Sun Y.Clinical trials of new anticancer agents in recent years in China[J].Japanese J Cancer & Chemotherapy,2002,29(Suppl 1):86.
  • 6Mouridsen H,Gershanovich M,Sun Y,et al.Superior efficacy of Letrozole(Femara)versus Tamoxifen as firwt-line therapy for postmanopausal women with advanced breast cancer:results of a phase Ⅲ study of the international Letrozole Breast Cancer Group[J].J Clinical Oncology,2001,19(10):2 596.
  • 7Mouridsen H,Sun Y,Gershanovich M,et al.Significant longer time to progression for Femara(letroxzole)in patients with or without prior adiuvant tamoxefen:updated analysis of the doubleb lind,randomized,nmhinational phase Ⅲ tril of letrozole compared to tamoxifen as first-line hormaonal therapy for advanced breast cancer[J].Breast Caricer Res Treat 2002,76(Suppl):256a.
  • 8Li H,Qin S,Ye SL,et al.A phase Ⅰ/Ⅱ study of hepatic delivery of doxombiein adsorbed to magnetic targeted carriers(MTC-DOX)in patients with unreseetable HCC[J].Proc ASCO,2003,22:1 422a.
  • 9Sun Y,Li H,Lin Z,et al.Phase Ⅰ pharmacokinetic study of nemorubiein hydrochloride Methoxymorpholino doxorubicin:PNU-152243) administered with iodinated oil via hepatic artery(IH)to patients(PT)with unresectable hepatocellular carcinoma(HCC)[J].Proc ASCO,2003,22:1 448a.
  • 10孙燕,何友兼,许立功,勇威本,周立强,李维廉,李丽庆,叶小平,张和平,陈荣楷,朱军.美罗华治疗B细胞淋巴瘤Ⅱ期临床验证报告[J].中国新药杂志,1999,8(12):822-824. 被引量:27

二级参考文献86

共引文献762

同被引文献239

引证文献16

二级引证文献114

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部